These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 2571812)

  • 1. Intensive treatment of multiple myeloma and criteria for complete remission.
    Gore ME; Selby PJ; Viner C; Clark PI; Meldrum M; Millar B; Bell J; Maitland JA; Milan S; Judson IR
    Lancet; 1989 Oct; 2(8668):879-82. PubMed ID: 2571812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. VAMP followed by high dose melphalan and autologous bone marrow transplantation for multiple myeloma.
    McElwain TJ; Gore ME; Meldrum M; Viner C; Judson IR; Malpas JS
    Bone Marrow Transplant; 1989 Dec; 4 Suppl 4():109-12. PubMed ID: 2697419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose chemotherapy and autologous bone marrow transplantation for myeloma.
    McElwain TJ; Selby PJ; Gore ME; Viner C; Meldrum M; Millar BC; Malpas JS
    Eur J Haematol Suppl; 1989; 51():152-6. PubMed ID: 2697587
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results in multiple myeloma after high-dose melphalan and autologous transplantation according to response categories in the era of old drugs.
    Martino M; Postorino M; Gallo GA; Messina G; Neri S; Piro E; Gentile M; Moscato T; Monteleone R; Fedele R; Mazzone C; Console G; Penna G; Alati C; Vincelli ID; Irrera G; Musolino C; Ronco F; Molica S; Morabito F
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):148-54. PubMed ID: 24417912
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma.
    Cunningham D; Paz-Ares L; Milan S; Powles R; Nicolson M; Hickish T; Selby P; Treleavan J; Viner C; Malpas J
    J Clin Oncol; 1994 Apr; 12(4):759-63. PubMed ID: 8151319
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Satisfactory remission in a case of IgD myeloma: effectiveness of glucocorticoid treatment.
    Takemori N; Kondo K; Kawamura T; Imai K; Sakurai H; Sato T
    Am J Hematol; 2001 Jan; 66(1):62-3. PubMed ID: 11426497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to induction chemotherapy is not essential to obtain survival benefit from high-dose melphalan and autotransplantation in myeloma.
    Singhal S; Powles R; Sirohi B; Treleaven J; Kulkarni S; Mehta J
    Bone Marrow Transplant; 2002 Nov; 30(10):673-9. PubMed ID: 12420206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Maintenance therapy for remission in myeloma with Intron A following high-dose melphalan and either an autologous bone marrow transplantation or peripheral stem cell rescue.
    Powles R; Raje N; Cunningham D; Malpas J; Milan S; Horton C; Mehta J; Singhal S; Viner C; Treleaven J
    Stem Cells; 1995 Aug; 13 Suppl 2():114-7. PubMed ID: 8520498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Recent therapy for refractory myeloma].
    Togawa A
    Rinsho Ketsueki; 1993 Apr; 34(4):450-4. PubMed ID: 8510332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcome assessment of a population-based group of 195 unselected myeloma patients under 70 years of age offered intensive treatment.
    Powles R; Raje N; Milan S; Millar B; Shepherd V; Mehta J; Singhal S; Kulkarni S; Viner C; Gore M; Cunningham D; Treleaven J
    Bone Marrow Transplant; 1997 Sep; 20(6):435-43. PubMed ID: 9313875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of vincristine and doxorubicin infusional chemotherapy with methylprednisolone (VAMP) with the addition of weekly cyclophosphamide (C-VAMP) as induction treatment followed by autografting in previously untreated myeloma.
    Raje N; Powles R; Kulkarni S; Milan S; Middleton G; Singhal S; Mehta J; Millar B; Viner C; Raymond J; Treleaven J; Cunningham D; Gore M
    Br J Haematol; 1997 Apr; 97(1):153-60. PubMed ID: 9136958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Recent progress in the treatment of hematological malignancies. V. Therapy of multiple myeloma].
    Imamura Y
    Nihon Naika Gakkai Zasshi; 1989 Jun; 78(6):809-13. PubMed ID: 2677178
    [No Abstract]   [Full Text] [Related]  

  • 13. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
    Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
    Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High dose chemotherapy followed by autologous haemopoietic stem cell transplant in multiple myeloma.
    Kumar L; Raju GM; Ganessan K; Shawgi S; Menon H; Wadhwa J; Sharma A; Singh R; Kochupillai V
    Natl Med J India; 2003; 16(1):16-21. PubMed ID: 12715951
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high-dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments.
    Alvares CL; Davies FE; Horton C; Patel G; Powles R; Sirohi B; Zuha R; Gatt A; Saso R; Treleaven JG; Dearden CE; Potter MN; Ethell ME; Morgan GJ
    Br J Haematol; 2005 Jun; 129(5):607-14. PubMed ID: 15916682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an 'operational cure'?
    Powles R; Sirohi B; Kulkarni S; Treleaven J; Rudin C; Sankpal S; Goyal S; Horton C; Millar B; Saso R; Singhal S; Mehta J
    Bone Marrow Transplant; 2002 Oct; 30(8):479-84. PubMed ID: 12379885
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Re-use of the original infusional induction chemotherapy as salvage therapy in myeloma patients relapsing after one autograft.
    Sirohi B; Powles R; Rudin C; Singhal S; Kulkarni S; Saso R; Horton C; Mehta J; Treleaven J
    Hematology; 2005 Oct; 10(5):361-4. PubMed ID: 16203605
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
    Lokhorst HM; Sonneveld P; Cornelissen JJ; Joosten P; van Marwijk Kooy M; Meinema J; Nieuwenhuis HK; van Oers MH; Richel DJ; Segeren CN; Veth G; Verdonck LF; Wijermans PW
    Bone Marrow Transplant; 1999 Feb; 23(4):317-22. PubMed ID: 10100574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Infused vincristine and adriamycin with high dose methylprednisolone (VAMP) in advanced previously treated multiple myeloma patients.
    Forgeson GV; Selby P; Lakhani S; Zulian G; Viner C; Maitland J; McElwain TJ
    Br J Cancer; 1988 Oct; 58(4):469-73. PubMed ID: 3207601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
    Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.